EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Atezolizumab Plus Bevacizumab for TACE ‐Unsuitable Intermediate‐Stage HCC Beyond Up‐To‐7 Criteria: Final Analysis of REPLACEMENT

Kazuomi Ueshima iD, Kaoru Tsuchiya iD, Tatsuya Yamashita, Shigeo Shimose iD, Kazushi Numata, Yuzo Kodama, Shinji Itoh iD, Yasuhito Tanaka iD, Hidekatsu Kuroda iD, Kazuyoshi Ohkawa, Teiji Kuzuya iD, Masafumi Ikeda und 8 weitere

Liver International · 2025

DOI: 10.1111/liv.70379 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Liver International, 2025. Verfasst von Kazuomi Ueshima und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Bevacizumab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chugai Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The phase II REPLACEMENT study showed promising clinical benefit from atezolizumab plus bevacizumab in transcatheter arterial chemoembolization (TACE)–naïve patients with intermediate‐stage hepatocellular carcinoma (HCC) beyond up‐to‐7 criteria, meeting its primary endpoint of progression‐free survival (PFS). Here, we report the final overall survival (OS) analysis.

Methods

Enrolled patients were naïve to TACE with unresectable intermediate‐stage HCC beyond up‐to‐7 criteria, had Child‐Pugh A, Eastern Cooperative Oncology Group performance status 0/1 and received no previous systemic therapy. Atezolizumab 1200 mg and bevacizumab 15 mg/kg were administered every 3 weeks. The primary endpoint was the 6‐month PFS rate by modified Response Evaluation Criteria in Solid Tumours for HCC (mRECIST); secondary endpoints included OS, PFS by RECIST version 1.1, objective response rate (ORR) and safety.

Results

Overall, 74 patients were enrolled between December 2020 and September 2021. At the clinical cut‐off date (March 31, 2024), median follow‐up was 33.6 months. Median PFS by mRECIST was 9.1 months (95% CI 7.1–10.2). Median OS was 33.8 months (95% CI 22.6–not estimable). ORR was 40.5% (95% CI 29.3–52.6), with 12.2% of patients having a complete response. Overall, 82.4% of patients received subsequent therapy. All‐cause adverse events (AEs) were observed in 98.6% of patients, most commonly hypertension (71.6%) and proteinuria (54.1%). Grade 3/4 AEs occurred in 43.2% of patients; no Grade 5 AEs were reported.

Conclusions

These results show that atezolizumab plus bevacizumab can be an alternative treatment option for patients with intermediate‐stage HCC beyond up‐to‐7 criteria who are deemed unsuitable for TACE. Trial Registration jRCTs071200051

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsBevacizumabAntibodies, Monoclonal, HumanizedChemoembolization, TherapeuticAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedProgression-Free SurvivalNeoplasm StagingResponse Evaluation Criteria in Solid TumorsAdult

Stichwörter der Autor:innen

atezolizumabbevacizumabhepatocellular carcinomatranscatheter arterial chemoembolization (TACE)

Substanzen

BevacizumabAntibodies, Monoclonal, Humanizedatezolizumab

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Department of Gastroenterology and Hepatology, Japanese Red Cross Musashino Hospital, Tokyo, Japan.
  • Department of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan.
  • Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
  • Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan.
  • Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

ORCID-Profile: Kazuomi Ueshima, Kaoru Tsuchiya, Shigeo Shimose, Shinji Itoh, Yasuhito Tanaka, Hidekatsu Kuroda, Teiji Kuzuya, Michihisa Moriguchi, Ryosuke Tateishi, Sadahisa Ogasawara, Masatoshi Kudo

Förderung

  • Chugai Pharmaceutical

Zitieren

APA

Ueshima, K., Tsuchiya, K., Yamashita, T., Shimose, S., Numata, K., Kodama, Y., Itoh, S., Tanaka, Y., Kuroda, H., Ohkawa, K., Kuzuya, T., Ikeda, M., Kooka, Y., Aikata, H., Hiraoka, A., Moriguchi, M., Tateishi, R., Ogasawara, S., Yamamoto, K., & Kudo, M. (2025). Atezolizumab Plus Bevacizumab for TACE ‐Unsuitable Intermediate‐Stage HCC Beyond Up‐To‐7 Criteria: Final Analysis of REPLACEMENT. Liver International. https://doi.org/10.1111/liv.70379

Vancouver

Ueshima K, Tsuchiya K, Yamashita T, Shimose S, Numata K, Kodama Y, et al. Atezolizumab Plus Bevacizumab for TACE ‐Unsuitable Intermediate‐Stage HCC Beyond Up‐To‐7 Criteria: Final Analysis of REPLACEMENT. Liver International. 2025. doi:10.1111/liv.70379

BibTeX
@article{Ueshima2025,
  author = {Ueshima, Kazuomi and Tsuchiya, Kaoru and Yamashita, Tatsuya and Shimose, Shigeo and Numata, Kazushi and Kodama, Yuzo and Itoh, Shinji and Tanaka, Yasuhito and Kuroda, Hidekatsu and Ohkawa, Kazuyoshi and Kuzuya, Teiji and Ikeda, Masafumi and Kooka, Youhei and Aikata, Hiroshi and Hiraoka, Atsushi and Moriguchi, Michihisa and Tateishi, Ryosuke and Ogasawara, Sadahisa and Yamamoto, Kouji and Kudo, Masatoshi},
  title = {Atezolizumab Plus Bevacizumab for TACE ‐Unsuitable Intermediate‐Stage HCC Beyond Up‐To‐7 Criteria: Final Analysis of REPLACEMENT},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70379}
}
Kostenlos starten →